Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort

Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort

Background: Rituximab has become one of the first-line therapies for the treatment of moderate and high-risk primary membranous nephropathy (pMN). We retrospectively reviewed 95 patients with pMN who received rituximab therapy and focused on the therapeutic effects and safety of this therapy in a Ch...

Full description

Bibliographic Details
Main Authors: Shuang Gao, Zhao Cui, Xin Wang, Yi-miao Zhang, Fang Wang, Xu-yang Cheng, Li-qiang Meng, Fu-de Zhou, Gang Liu, Ming-hui Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Medicine
Subjects:
primary membranous nephropathy
CD20 monoclonal antibody
rituximab
anti-PLA2R antibody
first line treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.663680/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.663680/full

Similar Items